Michael Gardner's Research Focus
Since joining SBP in 2015, Mr. Gardner has introduced a number of ADME (Absorption / Distribution / Metabolism / Excretion) assays crucial to the Prebys Center’s drug discovery capabilities. From its humble beginnings providing data on microsomal and plasma stability, the Bioanalytical/DMPK group now has a total of six assays in its mission to provide a one-stop shop for all Prebys Center ADME needs. Current assays include plasma protein binding, solubility, Log D partition coefficient, PAMPA (Parallel Artificial Membrane Permeability Assay), Cytochrome C P450 inhibition and a Caco-2 cell-based permeability assay. The group is constantly working to expand the suite of available assays.
Michael Gardner's Bio
Prior to joining the Sanford Burnham Prebys Medical Discovery Institute (SBP) in 2015, Mr. Gardner spent 15 years working in the field of Bioanalytical Chemistry and Drug Metabolism; first with Merck Research Labs (2000-2005) followed by his position with Ambit Biosciences (2005-2015). Within these organizations he served on many cross-disciplinary project teams and provided critical support to both lead op and early clinical programs. His early work on Quizartinib (AC220) led to its rapid promotion as a lead candidate for the potential treatment of acute myeloid leukemia.
Before embarking on a career in industry, Mr. Gardner spent 22 years doing academic research at UC San Diego in the Department of Medicine. His early work focused primarily on the purification and characterization of Phospholipase A1. As the lab evolved, he acquired critical skills in synthetic chemistry, HPLC, and pharmacokinetics, including in vivo tissue distribution studies of proprietary antiviral compounds.
In 2015, Mr. Gardner established the Bioanalytical/DMPK group at SBP to provide in vitro support to the Prebys Center’s drug discovery program. He continues to expand the suite of assays available to the medicinal chemistry group, and his broad background has been of benefit to many, both within and outside of the Prebys Center.
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE, Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, Holladay MW
Mol Cancer Ther 2012 Apr ;11(4):930-41
Reger TS, Zunic J, Stock N, Wang B, Smith ND, Munoz B, Green MD, Gardner MF, James JP, Chen W, Alves K, Si Q, Treonze KM, Lingham RB, Mumford RA
Bioorg Med Chem Lett 2010 Feb 1 ;20(3):1173-6
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS
Blood 2009 Oct 1 ;114(14):2984-92